| Document |
Document Title |
|
WO/2023/207545A1 |
The present invention provides an activated gain-of-function mutant of branched-chain amino acid transaminase 1 (BCAT1), and use thereof. In particular, the present invention provides a human BCAT1E61A gain-of-function activated mutant p...
|
|
WO/2023/206616A1 |
Provided is use of CTC-497E21.4 as a ferroptosis regulation and control target in preparing a gastric cancer-targeted drug. By means of interfering with the expression of CTC-497E21.4, the expression of SLC7A11 is regulated and controlle...
|
|
WO/2023/210657A1 |
The purpose of the present invention is to provide a method for preventing or treating myopia, and a composition used in said method. The present invention provides a method and composition for inhibiting, improving, or treating myopia b...
|
|
WO/2023/209708A1 |
Methods of treating a disease or disorder associated with a down or up-regulation of an immune response of a subject are disclosed. The methods comprising administering to the subject a therapeutically effective amount of any one or more...
|
|
WO/2023/207398A1 |
Provided is use of nintedanib or a pharmaceutically acceptable salt thereof in preparing a drug for the treatment of tuberculosis. The nintedanib or the pharmaceutically acceptable salt thereof is used in combination with other anti-tube...
|
|
WO/2023/209591A1 |
A pharmaceutical product, wherein an antibody-drug conjugate in which a drug-linker represented by the following formula (I) (wherein A represents a connecting position to an antibody) is conjugated to the antibody via a thioether bond, ...
|
|
WO/2023/210713A1 |
Provided is a drug usable as pharmaceutical for promoting the regeneration of epicardial cells and treating heart damage. A p21 inhibitor is used as the epicardial cell regeneration promoter.
|
|
WO/2023/211728A1 |
Methods of promoting healing of a wound in a dermal location of a subject are provided. Aspects of the methods may include administering an effective amount of a Piezo inhibitor composition to the wound to promote healing of the wound, e...
|
|
WO/2023/211888A1 |
The present disclosure provides methods of using combination therapies to treat cancer. These methods are based on inhibiting cyclin proteins along with proteins along the Cyclin Axis. Thus, a method of the disclosure may generally be pr...
|
|
WO/2023/210401A1 |
The purpose of the present invention is to elucidate the relationship between lymph vessels in the skin and lymphedema as well as the relationship between lymph vessels in the skin and the skin, and to provide thereby a method for evalua...
|
|
WO/2023/212623A1 |
Some embodiments of the invention include inventive compounds (e.g., boron compounds of Formula (I)), inventive lipid particles, and inventive lipoplexes. Other embodiments include compositions (e.g., pharmaceutical compositions) compris...
|
|
WO/2023/210585A1 |
The present invention provides a means for targeting a substance to motor nerve cells. Provided is a targeting agent for a motor nerve cell synapse including an antibody that can bind to an in-vesicle domain of synaptotagmin 2.
|
|
WO/2023/206896A1 |
The present invention provides use of an AKT inhibitor IV in the preparation of a reagent for inhibiting bacterial metabolism and growth. The AKT inhibitor IV can be used as a new reagent for antibiotic effects, and can effectively inhib...
|
|
WO/2023/209046A1 |
The present disclosure provides methods of treating multiple sclerosis associated spasticity or neurological pain in a patient with renal impairment by administering cannabinoids oromucosal spray.
|
|
WO/2023/205865A1 |
This invention refers to a herbal formulation to treat sexual dysfunctions. More specifically, the present invention relates to a herbal formulation containing standardized extract of Spilanthes acmella, useful as an adjuvant in the prev...
|
|
WO/2023/205794A1 |
The present disclosure provides a method of treating a disease or disorder (e.g., cancer) in a subject. The method including administering to the subject: a) a therapeutically effective amount of a PTPN11 inhibitor; and b) a therapeutica...
|
|
WO/2023/204397A1 |
The present invention relates to a pharmaceutical composition comprising: a first unit including acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and a second unit comprising a proton pump inhibitor. The pharmaceutical...
|
|
WO/2023/204290A1 |
The present invention addresses the problem of providing a new acellular preparation that need not be prepared for each patient individually and can stably and inexpensively achieve a high killing effect on tumor cells. Provided is a m...
|
|
WO/2023/202280A1 |
Provided are an anti-B7H6 scFv antibody, a coding gene thereof, and an application thereof. A B7H6-CAR-T cell includes an antibody or an antigen-binding fragment thereof targeting a B7H6 antigen, containing a heavy chain variable region ...
|
|
WO/2023/204734A1 |
The invention relates to the chemical and pharmaceutical industry and the medical industry and concerns the production of novel pharmaceutical dosage forms and medical products suitable for vaginal delivery, which can be used for the pre...
|
|
WO/2023/203223A1 |
There is herein provided a pharmaceutical formulation comprising one or more compounds that are β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and β3-adrenergic receptor agonist, or a pharmaceutically ac...
|
|
WO/2023/204259A1 |
Provided is a pharmaceutical which is for treating or preventing cancer, which comprises a compound represented by formula (1), a salt thereof, or solvate of these, and which is used together with a molecular-targeted agent, wherein the ...
|
|
WO/2023/202705A1 |
An ophthalmic preparation and an application thereof in treating presbyopia. The ophthalmic preparation comprises aceclidine and rebamipide, wherein aceclidine and rebamipide jointly have a synergistic effect. Rebamipide can enhance the ...
|
|
WO/2023/205649A1 |
This disclosure relates to use of tough organogels in drug delivery. Specifically, this disclosure relates to use of crosslinked elastomer organogels and organogles of polyurethanes modified with one or more lipophilic groups in drug del...
|
|
WO/2023/205183A1 |
Compositions for intravenous infusion of istaroxime in human patients suffering from pre-cardiogenic shock or cardiogenic shock are disclosed. Likewise, methods of administering istaroxime to individuals exhibiting symptoms of, or having...
|
|
WO/2023/203229A1 |
An agent that generates DNA replication stress and/or inhibits pathways involved in DNA replication stress tolerance for use in a method of treating a patient with cancer. The treatment comprises: determining whether the cancer expresses...
|
|
WO/2023/202563A1 |
Provided herein is a combination of an AKT inhibitor and a PIM kinase inhibitor for use in treating cancer, such as AKT inhibitor resistant cancer, in a subject in need thereof. Also provided is a composition comprising the same.
|
|
WO/2023/203163A1 |
The present invention relates to a compound of formula (I) and its use in the production of interleukin-10 by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relate...
|
|
WO/2023/204754A1 |
A method of treating an autoimmune skin disease in a patient comprising administering a therapeutically effective amount of a DHODH inhibitor or a pharmaceutically acceptable salt thereof. Also provided are formulations or compositions s...
|
|
WO/2023/203022A1 |
Provided is a PDE4 inhibitor, in particular orismilast or a pharmaceutically acceptable salt, solvate or hydrate thereof, for use in the treatment of neutrophilic dermatoses in a subject. In particular, the invention provides orismilast ...
|
|
WO/2023/205369A1 |
A pharmacotherapeutic protocol enhancing neuro-restoration in the human brain for patients suffering with brain injuries and diseases, wherein the protocol comprises treating the patient with a combinatorial pharmacological composition c...
|
|
WO/2023/204556A1 |
The present invention relates to a combination therapy of GLP-2 with an insulinotropic peptide, a TNFα inhibitor or both for preventing, alleviating or treating intestinal diseases.
|
|
WO/2023/204181A1 |
The present invention addresses the problem of providing a therapeutic agent for NK cell tumor. According to the present invention, a therapeutic agent for NK cell tumor is provided, which comprises a substance capable of recognizing a t...
|
|
WO/2023/203378A1 |
The present disclosure relates to the treatment and prevention of impaired cognitive function, cognitive decline and/or dementia or signs of cerebral neurodegeneration in a subject with diabetes mellitus by administration of a pharmaceut...
|
|
WO/2023/202091A1 |
Disclosed are the use of an AMPK inhibitor in combination with an HDAC inhibitor in the preparation of a drug for treating tumor diseases, and a composition. The AMPK inhibitor comprises compound C; and the HDAC inhibitor comprises TMP19...
|
|
WO/2023/205153A1 |
The present disclosure relates generally to the treatment of patients with chronic lung allograft dysfunction (CLAD) following lung transplantation, with bronchiolitis obliterans syndrome (BOS) following lung transplantation, or with bro...
|
|
WO/2023/203008A1 |
A composition comprising nicotinamide and low-molecular-weight HPMC and/or HPC, characterized in that the composition is formulated for oral administration with at least partially extended and/or sustained and/or controlled release of ni...
|
|
WO/2023/204170A1 |
Provided is a novel therapeutic agent useful for the prevention or treatment of lung inflammation and fibrosis, the agent containing, as an active ingredient, a compound which has an MMP2 inhibitory activity and is represented by formula...
|
|
WO/2023/203535A1 |
The present invention relates to 4-chromone derivative compounds of general formula (I) and the medical use thereof as anticancer agents.
|
|
WO/2023/202223A1 |
The present invention relates to a reagent for treating neuroendocrine prostate cancer and the use thereof. Specifically provided in the present invention is the use of the reagent in the preparation of a drug for treating or preventing ...
|
|
WO/2023/200738A1 |
Treatment of dilated cardiomyopathy in a subject by combination treatment with a tyrosine kinase inhibitor and a statin.
|
|
WO/2023/199057A1 |
Compositions for preventing and treating bacterial infections include artificial sweeteners such as ace-k, saccharin and cyclamate. The compositions are particularly envisaged for topical administration for treating skin infections and f...
|
|
WO/2023/200897A1 |
The present invention resides in the discovery that the viral homolog of human interleukin 6 (vIL-6) originated from Kaposi's sarcoma herpesvirus (KSHV), unlike human IL-6, does not trigger negative regulatory mechanisms during an inflam...
|
|
WO/2023/198611A1 |
The present invention relates to a composition for use in the treatment and/or prevention of dysbiosis of the microbiota in a subject, particularly the vaginal microbiota, wherein the composition comprises a lactoferrin and a sulphated p...
|
|
WO/2023/200427A1 |
A substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one derivative (represented by the formula (I)) free base's crystal form and salt's crystal form, a preparation method and application are provided; specifically, the...
|
|
WO/2023/197401A1 |
Provided are a biological gel formulation, a method for preparing same, and use thereof. The starting materials comprise hyaluronic acid, sodium chloride, sodium dihydrogen phosphate dodecahydrate, anhydrous sodium dihydrogen phosphate, ...
|
|
WO/2023/198868A1 |
The present invention relates to methods and pharmaceutical compositions for treating a macrophage-related disease comprising administering to a subject in need thereof an effective amount of one or more BET inhibitors or macrophages tre...
|
|
WO/2023/201318A1 |
Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an a...
|
|
WO/2023/199024A1 |
The invention relates to methods for promoting and maintaining cell differentiation and gene expression in a subject, and ensuring that longer genes are able to function, the method comprising administering citrate to a subject. The inve...
|
|
WO/2023/199927A1 |
The present invention addresses the problem of providing: an anti-TSPAN8-anti-CD3 bispecific antibody used in combination with a PD-1 signal inhibitor for treatment of a target cancer, or a pharmaceutical composition containing said bisp...
|
